Biochemical and behavioural characterization of EMPA, a novel high-affinity, selective antagonist for the OX(2) receptor.
about
Orexin receptors: pharmacology and therapeutic opportunitiesPhysiology of the orexinergic/hypocretinergic system: a revisit in 2012Orexin antagonists for neuropsychiatric disease: progress and potential pitfallsMultiple roles for orexin/hypocretin in addictionDual hypocretin receptor antagonism is more effective for sleep promotion than antagonism of either receptor aloneCrystal structure of the human OX2 orexin receptor bound to the insomnia drug suvorexantDiscovery of 5''-chloro-N-[(5,6-dimethoxypyridin-2-yl)methyl]-2,2':5',3''-terpyridine-3'-carboxamide (MK-1064): a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomniaOrexin signaling regulates both the hippocampal clock and the circadian oscillation of Alzheimer's disease-risk genesThe Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptorsOrexin receptor 2 expression in the posterior hypothalamus rescues sleepiness in narcoleptic miceEvaluation of potential PET imaging probes for the orexin 2 receptors.LSN2424100: a novel, potent orexin-2 receptor antagonist with selectivity over orexin-1 receptors and activity in an animal model predictive of antidepressant-like efficacy.Evaluation of JNJ-54717793 a Novel Brain Penetrant Selective Orexin 1 Receptor Antagonist in Two Rat Models of Panic Attack Provocation.Role of orexin/hypocretin in reward-seeking and addiction: implications for obesityHypocretin and its emerging role as a target for treatment of sleep disorders.Nicotine self-administration in the rat: effects of hypocretin antagonists and changes in hypocretin mRNA.A selective orexin-1 receptor antagonist attenuates stress-induced hyperarousal without hypnotic effectsThe role of orexins/hypocretins in alcohol use and abuse: an appetitive-reward relationship.Neuropeptides controlling energy balance: orexins and neuromedins.Radiosynthesis and evaluation of [11C]EMPA as a potential PET tracer for orexin 2 receptors.Orexin/hypocretin signaling at the orexin 1 receptor regulates cue-elicited cocaine-seeking.Discovery and development of orexin receptor antagonists as therapeutics for insomnia.Orexin/hypocretin based pharmacotherapies for the treatment of addiction: DORA or SORA?The hypocretin/orexin system: an increasingly important role in neuropsychiatry.Orexin OX2 Receptor Antagonists as Sleep Aids.Ligand-induced internalization of the orexin OX(1) and cannabinoid CB(1) receptors assessed via N-terminal SNAP and CLIP-tagging.Binding kinetics differentiates functional antagonism of orexin-2 receptor ligands.Nonpeptide orexin type-2 receptor agonist ameliorates narcolepsy-cataplexy symptoms in mouse models.Orexin and Central Modulation of Cardiovascular and Respiratory Function.Both Ox1R and Ox2R orexin receptors contribute to the cardiorespiratory response evoked from the perifornical hypothalamus.Hypocretin underlies the evolution of sleep loss in the Mexican cavefish.
P2860
Q24597418-BAD22205-F40B-4642-90C4-037F499B3A16Q26822470-0D39C1D7-11EE-489D-A292-925EFF0BD0C2Q26852653-F599A890-D310-4EB6-9A40-4F1FB5D85DC7Q27009536-82D72405-F271-43E8-A46A-8C0A42ABE694Q27300998-6048D2C5-6D9C-4A73-B775-9EE871D024FEQ27696899-AF7D32F3-6CAF-4885-9CCE-DA33C5FE2126Q28304842-949684E0-9D98-4A9A-A70E-A5B2EF9B25D6Q28315261-F210B4B2-40EA-445A-B5ED-963BCF737F0EQ30486707-32918D87-C4EE-42B3-B473-05AFA3035304Q30498843-71CBE6DA-35C0-44D2-8CEB-9A884F64385AQ30555478-201C268A-10A3-46FF-9AA5-8E1CB17243A1Q30569599-5EED51D5-9DF3-4B89-9C48-508178522AD1Q33780634-1677101D-1099-4D29-AA9D-F5F4CA10B007Q33915391-1977AF09-810D-47E1-A06B-E56FCEA9E7E4Q34155661-F3AA15A0-06DC-4626-90C9-D4F0D0D45B16Q35121048-490337B6-1C36-4510-B4F3-644E47DBB2FAQ35156407-EFDD2A06-43FA-422D-8900-14390EBC455DQ36417619-FE7630F5-D834-4301-8996-7B397DB9CA1CQ36531499-4AE64D1A-7F3F-443E-B4BA-9B18DF59869DQ36878958-AD166589-FA10-4462-B7A3-66D95137D73FQ37407124-A9BDB62F-AB11-4F63-AEC4-E5C52B31A94CQ37522859-D08BC710-9DB5-49EC-854F-FD75C5206A6EQ38221344-D5A24B44-D923-46E2-BB52-E340520BDAE4Q38231949-0A925B2F-FF90-47E7-A6A5-333A60F0348FQ39026714-17FFCA90-6902-4085-9FA9-F9C2F97F7302Q39617477-B76A6905-1BFD-4AC6-8218-91C583C10866Q41895360-AC0360F0-6254-4CEA-94A4-F6320F3C8F25Q44871025-E82A1B9E-0FB9-4084-8FEF-56B7EE237C73Q47357997-6D5B36F9-EB25-4113-80C5-7259DCF680F6Q47675929-650233F1-897A-4683-9906-C2A4A321329DQ48100550-9285AD37-DE3B-436E-AE7D-BEA150753AB5
P2860
Biochemical and behavioural characterization of EMPA, a novel high-affinity, selective antagonist for the OX(2) receptor.
description
2009 nî lūn-bûn
@nan
2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Biochemical and behavioural ch ...... gonist for the OX(2) receptor.
@ast
Biochemical and behavioural ch ...... gonist for the OX(2) receptor.
@en
type
label
Biochemical and behavioural ch ...... gonist for the OX(2) receptor.
@ast
Biochemical and behavioural ch ...... gonist for the OX(2) receptor.
@en
prefLabel
Biochemical and behavioural ch ...... gonist for the OX(2) receptor.
@ast
Biochemical and behavioural ch ...... gonist for the OX(2) receptor.
@en
P2093
P2860
P1476
Biochemical and behavioural ch ...... gonist for the OX(2) receptor.
@en
P2093
J G Wettstein
J-L Moreau
M Nettekoven
M Rogers-Evans
P Malherbe
P2860
P304
P356
10.1111/J.1476-5381.2009.00127.X
P407
P577
2009-04-01T00:00:00Z